LCZ696 (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. However, it is unclear whether LCZ696 can improve prognosis in patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent cardiac rupture after MI, probably due to the suppression of pro-inflammatory cytokines, matrix metalloproteinase-9 activity and aldosterone production, and enhancement of natriuretic peptides in mice. These findings suggest the mechanistic insight of cardioprotective effects of LCZ696 against acute MI, resulting in the belief that LCZ696 might be useful clinically to improve survival after acute MI.
CITATION STYLE
Ishii, M., Kaikita, K., Sato, K., Sueta, D., Fujisue, K., Arima, Y., … Tsujita, K. (2017). Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction. JACC: Basic to Translational Science, 2(6), 655–668. https://doi.org/10.1016/j.jacbts.2017.08.001
Mendeley helps you to discover research relevant for your work.